The optimization strategy leading to the identification of M4205, recently described in detail (31), focused on broad and potent coverage of disease-relevant mutations of KIT, offering superiority over approved SoC drugs for patients with unresectable metastatic or recurrent GIST (Fig. 1A). The gene discussed is KIT; the disease is gastrointestinal stromal tumor.